To explore if the non-IL2 blocking properties improve its efficacy, we sought to compare the efficacy of BT942 with daclizumab which blocks IL-2 signalling on IL-2R in the MC38 syngeneic tumor model in B-hIL2RA humanized mice. Here, IL2RA is linked to neoplasm.